TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Tonix Pharmaceuticals
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals received FDA clearance to proceed with a Phase 2 HORIZON study of TNX-102 SL, a potential new treatment for major depressive disorder, targeting 360 patients across 30 U.S. sites with planned enrollment in mid-2026.

Insights
AMD   negative

Experienced stock price decline despite strong results


TNXP   positive

Company is advancing a novel therapeutic approach for major depressive disorder, receiving FDA clearance and planning a pivotal clinical study with promising early signals of efficacy